Guerbet

Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer

17 июл 2023 10:00:19 Источник Nasdaq GlobeNewswire

Guerbet: Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development

10 июл 2023 08:48:16 Источник Nasdaq GlobeNewswire

Guerbet: Changes in Guerbet's Board of Directors

26 май 2023 08:29:04 Источник Nasdaq GlobeNewswire

Guerbet: Q1 2023 Revenue

20 апр 2023 08:49:25 Источник Nasdaq GlobeNewswire

Guerbet: 2022 annual results

22 мар 2023 09:45:58 Источник Nasdaq GlobeNewswire

Guerbet: 2022 revenue

09 фев 2023 08:46:34 Источник Nasdaq GlobeNewswire

Guerbet: 2023 Strategic Priorities

16 янв 2023 09:40:42 Источник Nasdaq GlobeNewswire

Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions

11 янв 2023 10:46:47 Источник Nasdaq GlobeNewswire

Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects

03 ноя 2022 10:04:18 Источник Nasdaq GlobeNewswire

Guerbet: Revenue at September 30, 2022

20 окт 2022 08:45:00 Источник Nasdaq GlobeNewswire

Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer

26 сен 2022 09:00:00 Источник Nasdaq GlobeNewswire

Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)

21 сен 2022 10:00:00 Источник Nasdaq GlobeNewswire

Guerbet: 2022 half-year results

21 сен 2022 08:45:00 Источник Nasdaq GlobeNewswire

Guerbet: Revenue at June 30, 2022

21 июл 2022 08:45:00 Источник Nasdaq GlobeNewswire

Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol

12 июн 2022 23:30:00 Источник Nasdaq GlobeNewswire

Guerbet: Q1 2022 revenue

21 апр 2022 08:45:00 Источник Nasdaq GlobeNewswire

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel

05 апр 2022 23:30:00 Источник Nasdaq GlobeNewswire

Guerbet - Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA - Priority Review granted by US-FDA March 28, 2022

29 мар 2022 09:05:55 Источник Nasdaq GlobeNewswire

Guerbet: 2021 annual results

23 мар 2022 09:45:00 Источник Nasdaq GlobeNewswire

Guerbet: Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization

07 мар 2022 09:00:48 Источник Nasdaq GlobeNewswire